Clinical Trial Update: 18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection [Phase 2]

View source ↗

Summary

Phase 2 trial assessing the imaging tracer 18F-FAPI-74 for cancer detection across multiple indications; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extrapulmonary Neuroendocrine Carcinoma
• Gastric Cancer
• Hepatocellular Carcinoma
• Mesothelioma
• Ovarian Cancer
• Pancreatic Ductal Adenocarcinoma
• Sarcoma
• Small Cell Lung Cancer

Drugs mentioned

• [18F] FAPI-74 (Fluorine-18 labeled fibroblast activation protein inhibitor FAPI-74)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Sarcoma, Small Cell Lung Cancer or Extrapulmonary Neuroendocrine Cancer (EP-NEC) | Phase 2 | Status: RECRUITING